Sunday, 20 January 2019
Latest news
Main » Price Target Overview of Celgene Corporation (NASDAQ:CELG)

Price Target Overview of Celgene Corporation (NASDAQ:CELG)

18 May 2018

In Q4 2017 Celgene Corp (NASDAQ:CELG) big money sentiment decreased to 0.83, according to Securities and Exchange Commission filings. Narrowing in a bit closer, the 5 month price index is 0.75305, the 3 month is 0.86692, and the 1 month is now 0.89308.

Another recent and important Saratoga Investment Corp. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company's stock valued at $121,000 after acquiring an additional 517 shares during the period. Funds holding Celgene Corp in top 10 decreased from 119 to 38 for a decrease of 81. Celgene Corp now has $58.09B valuation.

As of Q4 2017 Birchview Capital Lp has 45.52% invested in Celgene Corp. Robecosam AG acquired a new stake in shares of Celgene in the third quarter valued at approximately $114,000. Moreover, Selkirk Management Llc reported 260,000 shares in Celgene Corp equivalent to 14.49% of its equity exposure.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.22.35 is the P/E ratio. The companyÂ's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Celgene Corporation (NASDAQ:CELG) lost -$0.62 before the end of the regular trading session on Wednesday, hitting $81.36. Pzena Investment Mngmt Ltd Liability Corp stated it has 0% in Celgene Corporation (NASDAQ:CELG). It has underperformed by 19.15% the S&P500. Celgene had 35 analyst reports since December 8, 2017 according to SRatingsIntel. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. During the same period in the previous year, the company earned $1.68 earnings per share. equities research analysts anticipate that Celgene will post 7.63 earnings per share for the current year. Anchor Capital Advsrs owns 0.01% invested in Celgene Corporation (NASDAQ:CELG) for 2,300 shs. Assetmark Inc has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Whittier Tru holds 62,202 shares or 0.23% of its portfolio.

For more Celgene Corporation (NASDAQ:CELG) news brought out recently go to:,,, or Punch & Associate Inv Mngmt Incorporated has invested 0.26% in OFS Capital Corporation (NASDAQ:OFS). Jacobs Levy Equity Management, New Jersey-based fund reported 251,753 shs. When we say support, we mean the lower "floor" level where a company's stock may bounce back after falling.

Robeco Institutional Asset Management Bv owns 0.04% invested in Celgene Corporation (NASDAQ:CELG) for 71,073 shs. Bnp Paribas Arbitrage invested 0.1% in Celgene Corporation (NASDAQ:CELG). 529 hedge funds opened new and increased positions, while 634 cut down and sold their holdings in Celgene Corp so the sentiment dropped. Riverhead Mgmt Ltd holds 0.08% or 18,663 shs. Gm Advisory reported 5,304 shs or 0.15% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0.32% or 342,640 shs.

Since February 8, 2018, it had 1 insider buy, and 3 selling transactions for $3.58 million activity.

Lee Danner & Bass Inc. raised its stake in Celgene (NASDAQ:CELG) by 42.8% during the 1st quarter, Holdings Channel reports.

In total 20 analysts cover Celgene (NASDAQ:CELG). The stock has "Buy" rating by Compass Point on Friday, October 13. Тherefore 65% are bullish. With $152.0 highest and $90 lowest PT, Celgene has $122 average PT or 49.95% above the current ($81.36) price. (NASDAQ:CELG) has 36 ratings reports on 16 May 2018 according to StockzIntelligence. The rating was maintained by Leerink Swann on Friday, July 28 with "Outperform". The relative volume of the stock is 0.92, while its market cap is $60.88 Billion. The company rating was maintained by Canaccord Genuity on Tuesday, January 23. State Of Tennessee Treasury Department holds 0.36% in Celgene Corporation (NASDAQ:CELG) or 769,780 shares. SunTrust maintained Celgene Corporation (NASDAQ:CELG) on Thursday, January 25 with "Buy" rating. Credit Suisse Group set a $129.00 price target on shares of Celgene and gave the company a buy rating in a research note on Thursday, March 1st. ValuEngine downgraded Celgene from a "hold" rating to a "sell" rating in a report on Thursday, April 12th. On Monday, January 8 the company was maintained by SunTrust.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Friday, May 4th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.